Know Cancer

forgot password

Identification of Aberant Gene Expression in Human Prostatic Carcinoma

Open (Enrolling)
Prostate Cancer

Thank you

Trial Information

Identification of Aberant Gene Expression in Human Prostatic Carcinoma

The goal of this study is to identify novel genetic elements that are aberantly expressed
throughout prostatic neoplastic progression. The approaches proposed exploit the known
familial arm of prostatic cancer, using established molecular genetic approaches, and extend
these studies to sporadic prostatic cancer using a novel technique of differential display.
Application of the latter technique to colon cancer in the American population establishes
this tumor type as a high priority for scientific investigation and this study is part of an
initiative to address this problem. Presently the studies in the field of prostate are
under-represented. The collection of tissue samples from patients diagnosed with prostate
cancer. Patients will also provide a blood sample at the time of their surgery and
potentially post-op from 6 mos to 5 years. Samples will also be obtained from patients
who's biopsy turns out to be non-prostate cancer. These samples will be obtained shortly
following the biopsy out to 6 months after the biopsy.

Inclusion Criteria:

- Diagnosed prostate cancer undergoing prostatectomy

- Suspicion of prostate cancer undergoing biopsy - negative biopsy

- Health volunteer (control group) - blood sample for PSA

Exclusion Criteria:

- Patients not fitting the inclusion criteria

Type of Study:


Study Design:

Time Perspective: Prospective

Principal Investigator

John A Libertino, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Lahey Clinic


United States: Institutional Review Board

Study ID:




Start Date:

April 1995

Completion Date:

April 2025

Related Keywords:

  • Prostate Cancer
  • prostate cancer
  • Carcinoma
  • Prostatic Neoplasms



Lahey Clinic Burlington, Massachusetts  01805